eccogene glp 1 Elecoglipron Shows Positive Results in Phase 1b Trial in China Non‐clinical and first‐in‐human characterization of

Potential Side Effects Daytime drowsiness: Since DSIP may deepen slow-wave sleep, some users report feeling groggy if dosing is too high or mistimed

(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority

This aims to enhance access to GLP-1 medications for individuals enrolled in Medicare and Medicaid

We offer methylcobalamin (the active, methylated form, our default), hydroxocobalamin (a longer-acting storage form), and combination shots including MIC Lipo, glutathione, B-complex, Tri-Immune, and Vitamin D injections

Promotes A Positive Mood : Research indicates ALCAR supports feelings of well-being and mental energy through its interaction with cholinergic brain pathways